Dysfunctional intestinal microvascular endothelial cells: Insights and therapeutic implications in gastrointestinal inflammation-Immunometabolism-CSCIED科技核心评价数据库-手机版

Dysfunctional intestinal microvascular endothelial cells: Insights and therapeutic implications in gastrointestinal inflammation

Dysfunctional intestinal microvascular endothelial cells: Insights and therapeutic implications in gastrointestinal inflammation

ES评分 0 浏览量：1092 下载量：0

全文阅读下载引用收藏

DOI	10.1097/IN9.0000000000000043
刊名	Immunometabolism IJ
年，卷(期)	2024, 6(2)
作者	Park, Ji Seok; Cresci, Gail A. M.,
作者单位	[Park, Ji Seok; Cresci, Gail A. M.] Cleveland Clin, Digest Dis Inst, Dept Gastroenterol Hepatol & Nutr, Cleveland, OH 44106 USA; [Park, Ji Seok; Cresci, Gail A. M.] Cleveland Clin, Lerner Res Inst, Dept Inflammat & Immun, Cleveland, OH 44106 USA; [Cresci,
摘要	The intestinal microvascular endothelium plays a crucial role in orchestrating host responses to inflammation within the gastrointestinal tract. This review delves into the unique aspects of intestinal microvascular endothelial cells, distinct from those of larger vessels, in mediating leukocyte recruitment, maintaining barrier integrity, and regulating angiogenesis during inflammation. Specifically, their role in the pathogenesis of inflammatory bowel diseases, where dysregulated endothelial functions contribute to the disease progression, is reviewed. Furthermore, this review discusses the isolation technique for these cells and commonly used adhesion molecules for in vitro and in vivo experiments. In addition, we reviewed the development and therapeutic implications of a biologic agent targeting the interaction between alpha 4 beta 7 integrin on T lymphocytes and mucosal addressin cellular adhesion molecule-1 on gut endothelium. Notably, vedolizumab, a humanized monoclonal antibody against alpha 4 beta 7 integrin, has shown promising outcomes in inflammatory bowel diseases and other gastrointestinal inflammatory conditions, including chronic pouchitis, immune checkpoint inhibitor-induced colitis, and acute cellular rejection post-intestinal transplantation.
Abstract	The intestinal microvascular endothelium plays a crucial role in orchestrating host responses to inflammation within the gastrointestinal tract. This review delves into the unique aspects of intestinal microvascular endothelial cells, distinct from those of larger vessels, in mediating leukocyte recruitment, maintaining barrier integrity, and regulating angiogenesis during inflammation. Specifically, their role in the pathogenesis of inflammatory bowel diseases, where dysregulated endothelial functions contribute to the disease progression, is reviewed. Furthermore, this review discusses the isolation technique for these cells and commonly used adhesion molecules for in vitro and in vivo experiments. In addition, we reviewed the development and therapeutic implications of a biologic agent targeting the interaction between alpha 4 beta 7 integrin on T lymphocytes and mucosal addressin cellular adhesion molecule-1 on gut endothelium. Notably, vedolizumab, a humanized monoclonal antibody against alpha 4 beta 7 integrin, has shown promising outcomes in inflammatory bowel diseases and other gastrointestinal inflammatory conditions, including chronic pouchitis, immune checkpoint inhibitor-induced colitis, and acute cellular rejection post-intestinal transplantation.
关键词	intestinal microvascular endothelial cells; leukocyte homing; inflammatory bowel disease; mucosal addressin cellular adhesion molecule-1; alpha(4)beta(7) integrin; vedolizumab
KeyWord	intestinal microvascular endothelial cells; leukocyte homing; inflammatory bowel disease; mucosal addressin cellular adhesion molecule-1; alpha(4)beta(7) integrin; vedolizumab
基金项目
页码	1-5

参考文献
相关文献

[1]. Dela Paz NG, D’Amore PA. Arterial versus venous endothelial cells. Cell Tissue Res. 2009;335(1):5-16.

[2]. Butcher EC, Picker LJ. Lymphocyte homing and homeostasis. Science. 1996;272(5258):60-6.

[3]. Swerlick RA, Lawley TJ. Role of microvascular endothelial cells in inflammation. J Investig Dermatol. 1993;100(1):S111-5.

[4]. Haraldsen G, Rugtveit J, Kvale D, et al. Isolation and longterm culture of human intestinal microvascular endothelial cells. Gut. 1995;37(2):225-34.

[5]. Salcedo R, Resau JH, Halverson D, et al. Differential expression and responsiveness of chemokine receptors (CXCR1–3) by human microvascular endothelial cells and umbilical vein endothelial cells. FASEB J. 2000;14(13):2055-64.

[6]. Binion DG, West GA, Ina K, et al. Enhanced leukocyte binding by intestinal microvascular endothelial cells in inflammatory bowel disease. Gastroenterology. 1997;112(6):1895-907.

[7]. Cromer WE, Mathis JM, Granger DN, et al. Role of the endothelium in inflammatory bowel diseases. World J Gastroenterol. 2011;17(5):578-93.

[8]. Sessa W. Molecular control of blood flow and angiogenesis: role of nitric oxide. J Thromb Haemost. 2009;7:35-7.

[9]. Binion DG, Fu S, Ramanujam KS, et al. iNOS expression in human intestinal microvascular endothelial cells inhibits leukocyte adhesion. Am J Physiol. 1998;275(3):G592-603.

[10]. Petersson J, Schreiber O, Steege A, et al. eNOS involved in colitis-induced mucosal blood flow increase. Am J Physiol Gastrointest Liver Physiol. 2007;293(6):G1281-7.

[11]. Spyridopoulos I, Luedemann C, Chen D, et al. Divergence of angiogenic and vascular permeability signaling by VEGF: inhibition of protein kinase C suppresses VEGF-induced angiogenesis, but promotes VEGF-induced, NO-dependent vascular permeability. Arterioscler Thromb Vasc Biol. 2002;22(6):901-6.

[12]. Hatoum OA, Binion DG, Otterson MF, et al. Acquired microvasc dysfunction in inflammatory bowel disease: loss of nitric oxide-mediated vasodilation. Gastroenterology. 2003;125(1):58-69.

[13]. Jiang H-Q, Thurnheer M, Zuercher A, et al. Interactions of commensal gut microbes with subsets of B-and T-cells in the murine host. Vaccine. 2004;22(7):805-11.

[14]. Lu Y, Li X, Liu S, et al. Toll-like receptors and inflammatory bowel disease. Front Immunol. 2018;9:72.

[15]. Heidemann J, Domschke W, Kucharzik T, et al. Intestinal microvascular endothelium and innate immunity in inflammatory bowel disease: a second line of defense? Infect Immun. 2006;74(10):5425-32.

[16]. Tolstanova G, Khomenko T, Deng X, et al. Neutralizing anti-vascular endothelial growth factor (VEGF) antibody reduces severity of experimental ulcerative colitis in rats: direct evidence for the pathogenic role of VEGF. J Pharmacol Exp Ther. 2009;328(3):749-57.

[17]. Danese S, Papa A, Saibeni S, et al. Inflammation and coagulation in inflammatory bowel disease: the clot thickens. Am J Gastroenterol. 2007;102(1):174-86.

[18]. Rieder F, Kessler SP, West GA, et al. Inflammation-induced endothelial-to-mesenchymal transition: a novel mechanism of intestinal fibrosis. Am J Pathol. 2011;179(5):2660-73.

[19]. Siddiqui MT, Han Y, Shapiro D, et al. The postbiotic butyrate mitigates gut mucosal disruption caused by acute ethanol exposure. Int J Mol Sci. 2024;25(3):1665.

[20]. Ibrahim A, Mbodji K, Hassan A, et al. Anti-inflammatory and anti-angiogenic effect of long chain n-3 polyunsaturated fatty acids in intestinal microvascular endothelium. Clin Nutr. 2011;30(5):678-87.

[21]. Lertkiatmongkol P, Liao D, Mei H, et al. Endothelial functions of platelet/endothelial cell adhesion molecule-1 (CD31). Curr Opin Hematol. 2016;23(3):253-9.

[22]. Wong D, Dorovini-Zis K. Regulation by cytokines and lipopolysaccharide of E-selectin expression by human brain microvessel endothelial cells in primary culture. J Neuropathol Exp Neurol. 1996;55(2):225-35.

[23]. Pusztaszeri MP, Seelentag W, Bosman FT. Immunohistochemical expression of endothelial markers CD31, CD34, von Willebrand factor, and Fli-1 in normal human tissues. J Histochem Cytochem. 2006;54(4):385-95.

[24]. Briskin M, Winsor-Hines D, Shyjan A, et al. Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am J Pathol. 1997;151(1):97-110.

[25]. Strauch UG, Mueller RC, Li XY, et al. Integrin αE (CD103) β7 mediates adhesion to intestinal microvascular endothelial cell lines via an E-cadherin-independent interaction. J Immunol. 2001;166(5):3506-14.

[26]. Berlin C, Berg EL, Briskin MJ, et al. α4β7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1. Cell. 1993;74(1):185-95.

[27]. Arihiro S, Ohtani H, Suzuki M, et al. Differential expression of mucosal addressin cell adhesion molecule-1 (MAdCAM-1) in ulcerative colitis and Crohn’s disease. Pathol Int. 2002;52(5-6):367-74.

[28]. Souza H, Elia C, Spencer J, et al. Expression of lymphocyte-endothelial receptor-ligand pairs, α4β7/MAdCAM-1 and OX40/OX40 ligand in the colon and jejunum of patients with inflammatory bowel disease. Gut. 1999;45(6):856-63.

[29]. Ogawa H, Binion DG, Heidemann J, et al. Mechanisms of MAdCAM-1 gene expression in human intestinal microvascular endothelial cells. Am J Physiol Cell Physiol. 2005;288(2):C272-81.

[30]. Picarella D, Hurlbut P, Rottman J, et al. Monoclonal antibodies specific for beta 7 integrin and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) reduce inflammation in the colon of scid mice reconstituted with CD45RBhigh CD4+ T cells. J Immunol. 1997;158(5):2099-106.

[31]. Kato S, Hokari R, Matsuzaki K, et al. Amelioration of murine experimental colitis by inhibition of mucosal addressin cell adhesion molecule-1. J Pharmacol Exp Ther. 2000;295(1):183-9.

[32]. Van Assche G, Rutgeerts P. Antiadhesion molecule therapy in inflammatory bowel disease. Inflamm Bowel Dis. 2002;8(4):291-300.

[33]. McLean LP, Cross RK. Integrin antagonists as potential therapeutic options for the treatment of Crohn’s disease. Expert Opin Investig Drugs. 2016;25(3):263-73.

[34]. Sandborn WJ, Feagan BG, Rutgeerts P, et al.; GEMINI 2 Study Group. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013;369(8):711-21.

[35]. Feagan BG, Rutgeerts P, Sands BE, et al.; GEMINI 1 Study Group. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369(8):699-710.

[36]. Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017;358:j4008.

[37]. Feagan B. Safety and positioning of vedolizumab in patients with inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2018;14(4):244-6.

[38]. Travis S, Silverberg MS, Danese S, et al.; EARNEST Study Group. Vedolizumab for the treatment of chronic pouchitis. N Engl J Med. 2023;388(13):1191-200.

[39]. Ferrante M, Declerck S, De Hertogh G, et al. Outcome after proctocolectomy with ileal pouch-anal anastomosis for ulcerative colitis. Inflamm Bowel Dis. 2008;14(1):20-8.

[40]. Shen B. Pouchitis: what every gastroenterologist needs to know. Clin Gastroenterol Hepatol. 2013;11(12):1538-49.

[41]. Shen B, Kochhar GS, Kariv R, et al. Diagnosis and classification of ileal pouch disorders: consensus guidelines from the International Ileal Pouch Consortium. Lancet Gastroenterol Hepatol. 2021;6(10):826-49.

[42]. Turina M, Pennington CJ, Kimberling J, et al. Chronic pouchitis after ileal pouch-anal anastomosis for ulcerative colitis: effect on quality of life. J Gastrointest Surg. 2006;10:600-6.

[43]. Landy J, Al-Hassi HO, Ronde E, et al. Innate immune factors in the development and maintenance of pouchitis. Inflamm Bowel Dis. 2014;20(11):1942-9.

[44]. Barnes EL, Agrawal M, Syal G, et al.; AGA Clinical Guidelines Committee. AGA clinical practice guideline on the management of pouchitis and inflammatory pouch disorders. Gastroenterology. 2024;166(1):59-85.

[45]. Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol. 2016;39(1):98-106.

[46]. Romano E, Kusio-Kobialka M, Foukas PG, et al. Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients. Proc Natl Acad Sci U S A. 2015;112(19):6140-5.

[47]. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443-54.

[48]. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. N Engl J Med. 2015;373(17):1627-39.

[49]. Weber JS, Kähler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012;30(21):2691-7.

[50]. Abu-Sbeih H, Ali FS, Alsaadi D, et al. Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor–induced colitis: a multi-center study. J ImmunoTher Cancer. 2018;6:1-11.

[51]. Dougan M, Wang Y, Rubio-Tapia A, et al. AGA clinical practice update on diagnosis and management of immune checkpoint inhibitor colitis and hepatitis: expert review. Gastroenterology. 2021;160(4):1384-93.

[52]. Grant D, Abu-Elmagd K, Mazariegos G, et al.; Intestinal Transplant Association. Intestinal transplant registry report: global activity and trends. Am J Transplant. 2015;15(1):210-9.

[53]. Matsumoto CS, Subramanian S, Fishbein TM. Adult intestinal transplantation. Gastroenterol Clin North Am. 2018;47(2):341-54.

[54]. Abu-Elmagd KM, Armanyous SR, Fujiki M, et al. Management of five hundred patients with gut failure at a single center: surgical innovation versus transplantation with a novel predictive model. Ann Surg. 2019;270(4):656-74.

[55]. Trentadue G, Dijkstra G. Current understanding of alloimmunity of the intestinal graft. Curr Opin Organ Transplant. 2015;20(3):286-94.

[56]. Zuber J, Shonts B, Lau S-P, et al. Bidirectional intragraft alloreactivity drives the repopulation of human intestinal allografts and correlates with clinical outcome. Sci Immunol. 2016;1(4):eaah3732.

[57]. Beduschi T, Garcia J, Jebrock J, et al. Vedolizumab for the treatment of refractory severe rejection in intestinal transplantation. Transplantation. 2017;101(6S2):S59.

[58]. Trentadue G, Kats-Ugurlu G, Blokzijl T, et al. Safe and successful treatment of acute cellular rejection of an intestine and abdominal wall transplant with vedolizumab. Transplant Direct. 2020;6(2):e527.

[59]. Kellersmann R, Lazarovits A, Grant D, et al. Monoclonal antibody against β7 integrins, but not β7 deficiency, attenuates intestinal allograft rejection in mice. Transplantation. 2002;74(9):1327-34.

[60]. Norsa L, Joly F, Busch A, et al. Vedolizumab after intestinal transplantation. Transplantation. 2017;101(6S2):S116.

引用本文

Park, Ji Seok; Cresci, Gail A. M.. Dysfunctional intestinal microvascular endothelial cells: Insights and therapeutic implications in gastrointestinal inflammation [J]. Immunometabolism. 2024; 6; (2). 1 - 5.

文献评论

相关学者

相关机构